NCT03647579View on ClinicalTrials.gov

Dexmedetomidine Versus Midazolam Added to Ketamine in Pediatric Patients Undergoing Bone Marrow Aspiration and Biopsy

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 30, 2018

Primary Completion Date

December 15, 2018

Study Completion Date

April 20, 2019

Conditions
Procedural Sedation and Analgesia During Bone Marrow Aspiration and Biopsy
Interventions
DRUG

midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine

midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine

DRUG

Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine

Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine

Trial Locations (1)

171516

South Egypt Cancer Institute, Assiut University, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT03647579 - Dexmedetomidine Versus Midazolam Added to Ketamine in Pediatric Patients Undergoing Bone Marrow Aspiration and Biopsy | Biotech Hunter | Biotech Hunter